Browse OAT

Summary
SymbolOAT
Nameornithine aminotransferase
Aliases HOGA; ornithine aminotransferase precursor; gyrate atrophy; GACR; HOGAASE; OKT; ornithine delta-aminotransfe ......
Chromosomal Location10q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Mitochondrion matrix
Domain PF00202 Aminotransferase class-III
Function

-

> Gene Ontology
 
Biological Process GO:0006520 cellular amino acid metabolic process
GO:0006525 arginine metabolic process
GO:0006527 arginine catabolic process
GO:0006536 glutamate metabolic process
GO:0006560 proline metabolic process
GO:0006561 proline biosynthetic process
GO:0007601 visual perception
GO:0008652 cellular amino acid biosynthetic process
GO:0009063 cellular amino acid catabolic process
GO:0009064 glutamine family amino acid metabolic process
GO:0009065 glutamine family amino acid catabolic process
GO:0009084 glutamine family amino acid biosynthetic process
GO:0010121 arginine catabolic process to proline via ornithine
GO:0016053 organic acid biosynthetic process
GO:0016054 organic acid catabolic process
GO:0019493 arginine catabolic process to proline
GO:0019544 arginine catabolic process to glutamate
GO:0034214 protein hexamerization
GO:0043648 dicarboxylic acid metabolic process
GO:0044282 small molecule catabolic process
GO:0044283 small molecule biosynthetic process
GO:0046394 carboxylic acid biosynthetic process
GO:0046395 carboxylic acid catabolic process
GO:0050953 sensory perception of light stimulus
GO:0051259 protein oligomerization
GO:0055129 L-proline biosynthetic process
GO:1901565 organonitrogen compound catabolic process
GO:1901605 alpha-amino acid metabolic process
GO:1901606 alpha-amino acid catabolic process
GO:1901607 alpha-amino acid biosynthetic process
Molecular Function GO:0004587 ornithine-oxo-acid transaminase activity
GO:0008483 transaminase activity
GO:0016769 transferase activity, transferring nitrogenous groups
GO:0030170 pyridoxal phosphate binding
GO:0043168 anion binding
GO:0048037 cofactor binding
Cellular Component GO:0005759 mitochondrial matrix
> KEGG and Reactome Pathway
 
KEGG hsa00330 Arginine and proline metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-70614: Amino acid synthesis and interconversion (transamination)
R-HSA-1430728: Metabolism
R-HSA-71291: Metabolism of amino acids and derivatives
Summary
SymbolOAT
Nameornithine aminotransferase
Aliases HOGA; ornithine aminotransferase precursor; gyrate atrophy; GACR; HOGAASE; OKT; ornithine delta-aminotransfe ......
Chromosomal Location10q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between OAT and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolOAT
Nameornithine aminotransferase
Aliases HOGA; ornithine aminotransferase precursor; gyrate atrophy; GACR; HOGAASE; OKT; ornithine delta-aminotransfe ......
Chromosomal Location10q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of OAT in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolOAT
Nameornithine aminotransferase
Aliases HOGA; ornithine aminotransferase precursor; gyrate atrophy; GACR; HOGAASE; OKT; ornithine delta-aminotransfe ......
Chromosomal Location10q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of OAT in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3960.226
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.7870.776
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1160.953
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.9960.0549
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.6920.316
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1150.958
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0130.975
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0930.962
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1030.961
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1490.931
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5620.83
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2110.159
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of OAT in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolOAT
Nameornithine aminotransferase
Aliases HOGA; ornithine aminotransferase precursor; gyrate atrophy; GACR; HOGAASE; OKT; ornithine delta-aminotransfe ......
Chromosomal Location10q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of OAT. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolOAT
Nameornithine aminotransferase
Aliases HOGA; ornithine aminotransferase precursor; gyrate atrophy; GACR; HOGAASE; OKT; ornithine delta-aminotransfe ......
Chromosomal Location10q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of OAT. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by OAT.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolOAT
Nameornithine aminotransferase
Aliases HOGA; ornithine aminotransferase precursor; gyrate atrophy; GACR; HOGAASE; OKT; ornithine delta-aminotransfe ......
Chromosomal Location10q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of OAT. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolOAT
Nameornithine aminotransferase
Aliases HOGA; ornithine aminotransferase precursor; gyrate atrophy; GACR; HOGAASE; OKT; ornithine delta-aminotransfe ......
Chromosomal Location10q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of OAT expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolOAT
Nameornithine aminotransferase
Aliases HOGA; ornithine aminotransferase precursor; gyrate atrophy; GACR; HOGAASE; OKT; ornithine delta-aminotransfe ......
Chromosomal Location10q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between OAT and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolOAT
Nameornithine aminotransferase
Aliases HOGA; ornithine aminotransferase precursor; gyrate atrophy; GACR; HOGAASE; OKT; ornithine delta-aminotransfe ......
Chromosomal Location10q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting OAT collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting OAT.
ID Name Drug Type Targets #Targets
DB00114Pyridoxal PhosphateSmall MoleculeAADAT, ABAT, AGXT, AGXT2, ALAS1, ALAS2, AZIN2, BCAT1, BCAT2, CBS, ......54
DB00129OrnithineSmall MoleculeARG1, ARG2, GATM, OAT, OAZ1, OAZ2, OAZ3, OTC, SLC25A15, SLC25A2, S ......14
DB02054GabaculineSmall MoleculeOAT1
DB02821CanalineSmall MoleculeOAT1